Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

14.29 +0.10 (+0.67%)
Streaming Delayed Price Updated: 10:48 AM EST, Feb 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 272,249
Open 14.20
Bid (Size) 14.28 (500)
Ask (Size) 14.29 (300)
Prev. Close 14.19
Today's Range 14.14 - 14.41
52wk Range 6.685 - 15.00
Shares Outstanding 1,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
3 Cash-Producing Stocks That Concern Us
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
3 Healthcare Stocks We Steer Clear Of
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also... 
Via StockStory
Topics Stocks

Performance

YTD
+12.8%
+12.8%
1 Month
+12.4%
+12.4%
3 Month
+27.6%
+27.6%
6 Month
+79.5%
+79.5%
1 Year
+74.6%
+74.6%

More News

Read More
News headline image
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Earnings Scheduled For October 30, 2025 ↗
Via Benzinga
News headline image
2 Reasons to Sell AMRX and 1 Stock to Buy Instead
Via StockStory
News headline image
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
1 Small-Cap Stock to Target This Week and 2 That Underwhelm
Via StockStory
News headline image
Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
3 Healthcare Stocks We’re Skeptical Of
Via StockStory
Topics Stocks
News headline image
Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal to Participate in Upcoming Investor Conferences
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Is Amneal Stock a Buy After Investment Firm Westshore Wealth Bought Over 1 Million Shares? ↗
Via The Motley Fool
News headline image
Natera, Amneal, Chemed, The Pennant Group, and HCA Healthcare Shares Are Soaring, What You Need To Know
Via StockStory
Topics Economy
News headline image
Amneal EVP Sells $1.6 Million in Shares as Stock Trades Near Multi-Year Highs ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Unpacking Q3 Earnings: Amneal (NASDAQ:AMRX) In The Context Of Other Generic Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Russell 2000 Stocks with Warning Signs
Via StockStory
News headline image
Amneal Receives U.S. FDA Approval for Iohexol Injection
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
3 Stocks Under $50 We Steer Clear Of
Via StockStory
News headline image
Pfizer, Amneal, Jazz Pharmaceuticals, BD, and DaVita Shares Skyrocket, What You Need To Know
Via StockStory
Topics Artificial Intelligence Stocks
News headline image
3 Value Stocks We Find Risky
Via StockStory
News headline image
Why Amneal (AMRX) Stock Is Up Today
Via StockStory
News headline image
Amneal Pharmaceuticals Inc (NASDAQ:AMRX) Q3 2025 Earnings: EPS Beats Estimates, Stock Surges on Raised Guidance ↗
Via Chartmill
Topics Earnings

Frequently Asked Questions

Is Amneal Pharmaceuticals, Inc. - Class A Common Stock publicly traded?
Yes, Amneal Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.
What exchange does Amneal Pharmaceuticals, Inc. - Class A Common Stock trade on?
Amneal Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Amneal Pharmaceuticals, Inc. - Class A Common Stock?
The ticker symbol for Amneal Pharmaceuticals, Inc. - Class A Common Stock is AMRX on the Nasdaq Stock Market
What is the current price of Amneal Pharmaceuticals, Inc. - Class A Common Stock?
The current price of Amneal Pharmaceuticals, Inc. - Class A Common Stock is 14.29
When was Amneal Pharmaceuticals, Inc. - Class A Common Stock last traded?
The last trade of Amneal Pharmaceuticals, Inc. - Class A Common Stock was at 02/03/26 10:48 AM ET
What is the market capitalization of Amneal Pharmaceuticals, Inc. - Class A Common Stock?
The market capitalization of Amneal Pharmaceuticals, Inc. - Class A Common Stock is 14.29K
How many shares of Amneal Pharmaceuticals, Inc. - Class A Common Stock are outstanding?
Amneal Pharmaceuticals, Inc. - Class A Common Stock has 14K shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.